Working... Menu

Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00004454
Recruitment Status : Completed
First Posted : October 19, 1999
Last Update Posted : June 24, 2005
University of Minnesota - Clinical and Translational Science Institute
Information provided by:
Office of Rare Diseases (ORD)

Brief Summary:

OBJECTIVES: I. Evaluate the safety and feasibility of treating mucopolysaccharidosis II (mild Hunter syndrome) by lymphocyte gene therapy.

II. Determine the levels of iduronate-2-sulfatase enzyme in these patients attained by infusing increasing doses of lymphocytes transduced with a retroviral vector designed for insertion and expression of this iduronate-2-sulfatase gene (L2SN).

III. Determine the duration of survival of these transduced cells in these patients.

IV. Determine whether monthly infusion of L2SN-transduced lymphocytes accomplishes metabolic correction (as measured by glycosaminoglycan excretion), decrease in liver or spleen volume, any therapeutic effect upon cardiac and pulmonary dysfunction, or any other effects from treatment.

Condition or disease Intervention/treatment Phase
Mucopolysaccharidosis II Genetic: lymphocyte gene therapy Phase 1 Phase 2

Detailed Description:

PROTOCOL OUTLINE: Peripheral blood lymphocytes are harvested from patient by apheresis, stimulated to initiate the growth of T-lymphocytes, transduced with retrovirus L2SN containing iduronate-2-sulfatase, and reinfused into the patient.

Patients receive 12 monthly infusions of these retroviral-mediated gene transduced lymphocytes with the first three infusions in a dose escalation format.

Patients are monitored for at least 2 hours after completion of each infusion. Patients are followed at 1 year after treatment, and then until death.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 2 participants
Primary Purpose: Treatment
Study Start Date : October 1996

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


--Disease Characteristics--

Mucopolysaccharidosis II (mild Hunter syndrome) as defined by the following:

  • Characteristic coarse facial features, hepatosplenomegaly, and radiographic evidence of dysostosis multiplex
  • Elevated urinary excretion of glycosaminoglycans in 3 urine specimens
  • Deficient iduronate-2-sulfatase enzyme activity as measured in plasma and leukocytes
  • Mutation consistent with mild Hunter syndrome must have either: A single base substitution of the coding sequence not previously associated with severe Hunter syndrome phenotype OR An exon-skipping mutation that would allow for occasional production of (minimal amounts of) normal protein

--Patient Characteristics--

Cardiovascular: No severe cardiac disease

Pulmonary: No severe respiratory disease


  • Must have IQ score of 80 or higher
  • Effective contraception required of all fertile patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00004454

Layout table for location information
United States, Minnesota
University of Minnesota Medical School
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
University of Minnesota - Clinical and Translational Science Institute
Layout table for investigator information
Study Chair: Chester B. Whitley University of Minnesota - Clinical and Translational Science Institute

Layout table for additonal information Identifier: NCT00004454     History of Changes
Other Study ID Numbers: 199/13577
First Posted: October 19, 1999    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: October 2003

Keywords provided by Office of Rare Diseases (ORD):
inborn errors of metabolism
mucopolysaccharidosis II
rare disease

Additional relevant MeSH terms:
Layout table for MeSH terms
Mucopolysaccharidosis II
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Connective Tissue Diseases
Metabolic Diseases
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Genetic Diseases, X-Linked
Heredodegenerative Disorders, Nervous System